The Roadmap
The Advisory plan: what I found, what matters now, what we are doing next, and what would change the course. I deliver it within 60 days.
The Method
The system, decisions, and cadence.
Management uses the Meier Management System. Advisory follows the questions and goals you bring. Both keep the plan visible as results return.
Meier Management System
A one-time setup feeds an approximately quarterly cycle.
Set up once
Benchmark
Establish baseline
Analyze
Form hypotheses
Engineer
Targets and protocol
Then every quarter
Execute
Act on the protocol
Measure
Update the evidence
Calibrate
Improve the next decision
↑ repeats
Feeding measure
- History and records
- Wearables and function
- Biomarkers: blood, urine, stool, saliva, and epigenetics
- Changing goals
- New concerns
Every system · Every quarter · Against your baseline
The written record
What I write down.
The Current State
The Management baseline after BENCHMARK, ANALYZE, and ENGINEER. It records the system, the priorities, and the first protocol.
Quarterly Healthspan Review
The written close of each Management cycle: what changed, what remains uncertain, and what I recommend next.
How I decide
Drivers, Goals, Targets, Levers: D-GTL.
Your history, records, goals, and results shape the working model. I form hypotheses about the Drivers, define Targets with numbers and sources, and select the Levers most likely to move them.
01
Drivers
The upstream factors and constraints that appear to be shaping the current state.
What is driving this?
02
Goals
The work, family, sport, function, or future capacity that health must support.
What must stay possible?
03
Targets
The measurable result the plan is built to move, with a number and a source.
What result are we targeting?
04
Levers
The interventions most likely to move the target: medications, supplements, nutrition, training, sleep, or testing.
What is most likely to move it?
What arrives, and when
Everything is written down and lives in your portal.
Management
The Current State
after Benchmark, Analyze, and Engineer
Quarterly Healthspan Review
plus a live conversation, each cycle
3 · 6 · 9 · 12 months
Advisory
Roadmap
in a dedicated session within 60 days
Quarterly review
plus a written recap and an updated Roadmap
3 · 6 · 9 · 12 months
Management
The Current State follows BENCHMARK, ANALYZE, and ENGINEER. It contains your physiological model, first D-GTL map, priorities, uncertainty, and starting protocol. Each cycle includes blood, urine, stool, saliva, and epigenetics, then ends with a written Quarterly Healthspan Review and a live conversation.
Advisory
Your records, goals, and missing baseline feed a Roadmap within 60 days. Quarterly reviews follow with a written recap and Roadmap revision as new results arrive.
Testing access
Modern tools, selected for the question.
I select modern imaging, connected wearables, continuous glucose monitoring, and physician-ordered cash-pay testing according to the individual question and the evidence. Most of the advanced testing and tools I use are cash-pay and sit outside the usual insurance authorization pathway. This lets the investigation follow the clinical question rather than an insurer's coverage rules. Their data becomes part of the longitudinal record and my working model.
01
Management measurement architecture
Each approximately quarterly cycle includes blood, urine, stool, saliva, and epigenetic measurement.
02
Added for the individual question
Genetic testing, imaging, DEXA, VO2 max, continuous glucose monitoring, connected wearables, and other tools are added according to your goals and the working hypotheses.
Labs and imaging carry no markup. Other third-party providers bill separately.
Reading the evidence
One value never stands alone.
I read a value beside the laboratory range and a target set from current research. I also look at its direction against your own baseline and at the behavior of the system around it. A pattern can matter before any single result leaves the laboratory range.
For example, blood sugar (fasting glucose) can rise for years while every annual report still calls it normal. Fasting insulin measures circulating insulin after an overnight fast. Read with fasting glucose, it can reveal elevated insulin despite normal-range glucose. From the two values, I calculate HOMA-IR and may add continuous glucose monitoring to guide risk reduction.
Trend before snapshot
A result can sit inside a lab range while moving in the wrong direction. Your baseline and the direction of travel carry more weight than a single reassuring label.
Risk tied to evidence
When I use a risk score or target, I pin it to the primary literature, state its limits, and separate an observed change from a plausible contribution.
Fit conversation · about 20 minutes
Tell me what you want to protect or improve.I'll tell you whether Advisory, Management, or neither is the right fit.